
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$6.44
−US$0.01 · -0.16%
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
前收盘价
US$6.44
−US$0.01 · -0.16%
盘后
US$6.42
−US$0.02 · -0.31%
10月12日 16:13 ET
盘中时间采用ET。市场数据可能有所延迟。
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
日内区间
当前US$6.44
52周区间
当前US$6.44
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
47
合理估值
情绪
52
多空交织
风险
68
高风险
动量
26
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
日内区间
当前US$6.44
52周区间
当前US$6.44
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 1.29亿 USD | 1.29亿 USD | 1.28亿 USD | 1.03亿 USD | 1.11亿 USD |
| 销货成本 | 8885.49万 USD | 8856.9万 USD | 8641.1万 USD | 7528.4万 USD | 7220.4万 USD |
| 毛利 | 4060.97万 USD | 4029.8万 USD | 4185万 USD | 2798.5万 USD | 3906.6万 USD |
| 研究与开发 | 850.3万 USD | 825.8万 USD | 857.5万 USD | 873.6万 USD | 783.9万 USD |
| 销售、一般及管理费用 | 3335.49万 USD | 4404.6万 USD | 4046.3万 USD | 3896.9万 USD | 3465.9万 USD |
| 营业费用 | 4186.63万 USD | 5754.3万 USD | 5069.4万 USD | 4978.1万 USD | 5085.7万 USD |
| 利息收入 | — | — | — | 6.8万 USD | 8.1万 USD |
| 利息支出 | −221.4万 USD | 2183.5万 USD | 1809万 USD | 1764.9万 USD | 1555.1万 USD |
| 折旧和摊销 | 949.89万 USD | 802.7万 USD | 795.4万 USD | 1317.7万 USD | 1806.1万 USD |
| 营业利润 | −125.66万 USD | −1724.5万 USD | −884.4万 USD | −2179.6万 USD | −1179.1万 USD |
| 净利润 | −3079.03万 USD | −3871.7万 USD | 1201.3万 USD | −9956.3万 USD | −1.17亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM476.9万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Total Stock Market ETFVTI366.66万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF194.19万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO72.94万0.00%180亿 USD0.06%US$112.27-0.35%
iShares Micro-Cap ETFIWC57.99万0.04%13.17亿 USD0.60%US$181.66-0.73%
Vanguard Russell 2000 Value ETFVTWV11.06万0.01%14亿 USD0.06%US$185.97+0.08%
iShares Russell 2500 ETFSMMD10.12万0.00%40.62亿 USD0.23%US$86.01-0.32%
Global X - Russell 2000 ETFRSSL8.78万0.01%14.19亿 USD0.08%US$108.72-0.34%
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
Vanguard Russell 2000 ETFVTWO
iShares Micro-Cap ETFIWC
Vanguard Russell 2000 Value ETFVTWV
iShares Russell 2500 ETFSMMD
Global X - Russell 2000 ETFRSSLAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。